Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma
Among patients who received two 3-week cycles of neoadjuvant ipilimumab and nivolumab, the 12-month event-free survival was 83.7%, as compared with 57.2% among those...
Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC
Among patients with EGFR-mutated lung cancer after chemoradiotherapy, 65% of patients who received osimertinib were alive without progression at 2 years, as compared with...
Phase 3 Trial of Crinecerfont in Pediatric Congenital Adrenal Hyperplasia
In this phase 3 trial, crinecerfont was superior to placebo in reducing elevated androstenedione levels and lowering glucocorticoid doses in pediatric participants with classic...
Phase 3 Trial of Crinecerfont in Pediatric Congenital Adrenal Hyperplasia
In this phase 3 trial, crinecerfont was superior to placebo in reducing elevated androstenedione levels and lowering glucocorticoid doses in pediatric participants with classic...
Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma
In patients with relapsed or refractory myeloma, 1-year progression-free survival was 20 percentage points higher with belantamab mafodotin, pomalidomide, and dexamethasone than with bortezomib,...
